Evidence Based Medicine presented by InpharmD™ InpharmD™
-
- Health & Fitness
-
We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.
-
Phenytoin for Tacrolimus Toxicity
InpharmD's EBM podcast focuses on commonly asked DI questions. Every day, our queue gets tons of new questions asked from providers all around the country. Today's podcast focuses on the use of phenytoin to treat tacrolimus toxicity.
-
Atypical Antipsychotics and QT–prolongation
InpharmD's EBM podcast focuses on commonly asked drug information questions. Every day, our queue gets tons of new questions asked from providers all around the country. One question that’s been garnering a lot of views from our users right now is which atypical antipsychotics are associated with the lowest and highest risk of QT prolongation.
-
Apixaban in Peripheral Artery Disease
Join InpharmD as we discuss the role of apixaban in peripheral artery disease.
-
Safety and Efficacy of RSV Vaccines
Join InpharmD as we discuss the safety and efficacy of two FDA-approved RSV vaccines, Arexvy and Abrysvo.
-
Safety and Efficacy of Rezafungin
Join us as we discuss the data surrounding newly approved antifungal agent, rezafungin. Interested in learning more? Join our CE on rezafungin on July 27th at 12:00 PM EST - open to all pharmacists!
-
Perioperative Duloxetine During Orthopedic Surgery for Pain Reduction
Join InpharmD as we discuss the data on perioperative duloxetine (Cymbalta) during orthopedic surgery for pain reduction.
Interested in the full data response? Read here!
Customer Reviews
Good, concise summaries, but
I appreciate the content and the straightforward drill down of information. It’s been useful to me as a clinical pharmacist. However, there seems to be at least one or two mispronunciations in each episode that causes me to cringe. Maybe have someone listen before publishing? Overall, great job though.